Technology
Inflammation biotech Electra charges up with $350M from upsized IPO
Inflammation-focused biotech Electra raised $350 million through an upsized initial public offering, joining a run of recent biotech listings.
After one failed acquisition attempt, Lisata finds lifeline in Marea merger
Lisata Therapeutics agreed to merge with Marea, securing a path forward after an earlier acquisition attempt fell through.
Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
Roche entered an agreement worth up to $1 billion with Dualitas to collaborate on screening bispecific antibody candidates.
SK pens $315M pact with fellow South Korean company for Parkinson’s prospect
SK signed a $315 million licensing pact with another South Korean company to advance a Parkinson's disease drug candidate.
Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
Artelo Biosciences reported preclinical data showing its cannabinoid agonist matched semaglutide on weight reduction in obese-mouse studies.
Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope
Novo Nordisk added three early-stage obesity drug candidates from Kallyope, extending its metabolic-disease pipeline.
Medtronic earns FDA clearance for LigaSure use with its Hugo robotic system
Medtronic received FDA clearance to use its LigaSure vessel-sealing device with the Hugo robotic surgical system.
FDA clears Aptitude’s latest Metrix molecular dx to test for COVID
Aptitude won FDA clearance for the latest version of its Metrix molecular diagnostic to test for COVID-19.
Xenon pauses phase 3 depression trials after psychosis events
Xenon Pharmaceuticals paused its phase 3 depression program after psychosis events were reported among trial participants.
BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data
Bristol Myers Squibb terminated a $100 million degrader-antibody conjugate collaboration with Orum Therapeutics after reviewing phase 1 data.